Drug Trial Radar · NCT06041776
Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations
Last checked: Nov 19, 2026Latest source record: Sep 22, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
570
Planned (sponsor's estimate)
Start
Mar 28, 2023
Primary completion
Apr 30, 2028
Study completion Nov 30, 2029
Sponsor
- Lead sponsor
- Betta Pharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This multicenter, randomized, controlled, double-blind, double-simulated, Phase III study is designed to evaluate the efficacy and safety of Befotertinib compared with Icotinib as adjuvant treatment in EGFR-sensitive mutation-positive stage IB-IIIB (T3N2M0) non-small cell lung cancer after surgical resection.
Conditions
- Non-Small Cell Lung Cancer
- EGFR Sensitive Mutation
- Adjuvant Therapy
Interventions
Befotertinib + Icotinib placeboDrug
The initial dose of Befotertinib is 75 mg orally once daily (QD) for 21 days, and then increased to 100 mg orally QD in the absence of serious side effects , CTCAE grade ≥ 2 headache or thrombocytopenia during the 21 days. Befotertinib can be taken on an empty stomach or after meals, and the medication is used until the disease relapses or intolerable toxicity occurs, or the treatment lasts for 3 years (disease recurrence includes local recurrence and/or distant metastasis) Icotinib placebo 125 mg three times daily, on an empty stomach or in combination with food, use medication until the disease relapses or intolerable toxicity occurs or treatment lasts for 2 years (disease recurrence includes local recurrence and/or distant metastasis).
Icotinib + Befotertinib placeboDrug
Icotinib 125 mg three times daily, on an empty stomach or in combination with food, use medication until the disease relapses or intolerable toxicity occurs or treatment lasts for 2 years (disease recurrence includes local recurrence and/or distant metastasis). The initial dose of Befotertinib placebo is 75 mg orally once daily (QD) for 21 days, and then increased to 100 mg orally QD in the absence of serious side effects , CTCAE grade ≥ 2 headache or thrombocytopenia during the 21 days. Befotertinib placebo can be taken on an empty stomach or after meals, and the medication is used until the disease relapses or intolerable toxicity occurs, or the treatment lasts for 3 years (disease recurrence includes local recurrence and/or distant metastasis.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease free survival (DFS) evaluated by investigator in patients with stage II-IIIB (T3N2M0)Time frame: up to 5 years
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Peking University International Hospital
Beijing, China · Recruiting
Jiangsu Cancer Hospital
Nanjing, China · Recruiting
Shanghai chest hospital
Shanghai, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.